137730-67-7

Basic information

• Product Name: spiro[indene-1,4'-piperidine] hydrochloride
• Synonyms: spiro[indene-1,4'-piperidine] hydrochloride;Spiro[indene-1,4'-piperidine] HCl;EOS-60442;4-spiroindene-piperidine HCl
• CAS NO: 137730-67-7
• Molecular Formula: C₁₃H₁₅N*ClH
• Molecular Weight: 221.729
• Mol File: 137730-67-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: spiro[indene-1,4'-piperidine] hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: spiro[indene-1,4'-piperidine] hydrochloride(137730-67-7)
• EPA Substance Registry System: spiro[indene-1,4'-piperidine] hydrochloride(137730-67-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 137730-67-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Spiro[indene-1,4'-piperidine] hydrochloride is used as a drug candidate for the development of new medications targeting central nervous system disorders. Its unique spiro structure and chemical properties make it a promising candidate for treating various neurological conditions.
Used in Anti-Inflammatory Applications:
In the field of anti-inflammatory research, spiro[indene-1,4'-piperidine] hydrochloride is being investigated for its potential as an anti-inflammatory agent. Its ability to modulate inflammatory responses could lead to the development of new treatments for conditions characterized by chronic inflammation.
Used in Medicinal Chemistry Research:
As a complex compound with potential therapeutic applications, spiro[indene-1,4'-piperidine] hydrochloride is used in medicinal chemistry research to explore its properties and understand its mechanisms of action. This research aims to optimize its therapeutic potential and identify new applications in the treatment of various diseases and conditions.

Upstream product

• 137419-24-0 1'-(tert-butyloxycarbonyl)spiro<1H-indene-1,4'-piperidine> 

Downstream Products

• 137419-04-6 (1S)-1'-<<(7,7-dimethyl-2-oxobicyclo<2.2.1>hept-1-yl)methyl>-sulfonyl>spiro(1H-indene-1,4'-piperidine) 

Relevant articles and documents

Serine derivatives and their use as therapeutic agents

The present invention relates to compounds of formula (I): STR1 wherein m is zero, 1 or 2; and n is zero or 1, with the proviso that the sum total of m+n is 1 or 2; R1 represents phenyl; naphthyl; benzhydryl; or benzyl, where the naphthyl group or any phenyl moiety may be substituted; R2 represents hydrogen; phenyl; heteroaryl selected from indazolyl, thienyl, furanyl, pyridyl, thiazolyl, tetrazolyl and quinolinyl; naphthyl; benzhydryl; or benzyl; wherein each heteroaryl, the naphthyl group and any phenyl moiety may be substituted; R3 and R4 each independently represents hydrogen or C1-6 alkyl or R3 and R4 together are linked so as to form a C1-3 alkylene chain; Q represents CR5 R6 or NR5 ; X and Y each independently represents hydrogen, or together form a group =O; and Z represents a bond, O, S, SO, SO2, NRc or --(CRc Rd)--, where Rc and Rd each independently represent hydrogen or C1-6 alkyl; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia.

Spiropiperidines as high-affinity, selective σ ligands

A variety of achiral conformationally restricted spirocyclic piperidines have been prepared in an attempt to investigate the functional role of the central σ recognition site. All the compounds possessed a lipophilic N- substituent incorporating either a tetralin, indan, or benzocycloheptane skeleton. Their in vitro affinity at the σ site was assessed in radioligand displacement experiments with guinea pig cerebellum homogenates using the σ- specific radioligand [3H]-N,N'-di-o-tolylguanidine ([3H]-DTG, [3H]-6). A study of the structure-activity relationships identified the N-butyl and N- dimethylallyl substituents as the optimum groups for high affinity and selectivity at the σ site (e.g., 3,4-dihydro-1'-(3-methylbut-2- enyl)spiro[1H-indene-1,4'-piperidine] (48), pIC50 = 8.9 vs [3H]-6 and greater than 10 000-fold selective over the dopamine D2 receptor). Such compounds are amongst the highest affinity σ ligands reported to date, with excellent selectivity over the dopamine D2 receptor, and may serve as a useful tool for exploring the physiological role of the σ site.

Orally Active, Nonpeptide Oxytocin Antagonists

The first nonpeptide antagonists of the neurohypophyseal hormone, oxytocin (OT) are described.Derivatives of the spiroindenepiperidine ring system, these compounds include L-366,509, an orally bioavailable OT antagonist with good in vivo duration.The potential use of these agents for treatment of preterm labor and their significance as new nonpeptide ligands for peptide receptors are discussed.

SPIROCYCLIC OXYTOCIN ANTAGONISTS

Disclosed are spirocyclic compounds of the formula: STR1 The compounds of formula I are oxytocin antagonists useful in the treatment of preterm labor and dysmenorrhea, and for the stoppage of labor preporatory to Caesarian delivery. Also disclosed are pharmaceutical compositions containing these compounds as well as methods for preparing the compounds.

Piperidinylcamphorsulfonyl oxytocin antagonists

Spirocyclic compounds of the formula: are oxytocin and vasopressin antagonists useful in the treatment of pre-term labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery, timing of parturition, uterine hyperactivity, endometriosis, hypertension, congestive heart failure, hyponatremia and cognitive disorders.

Use of spirocyclic compounds as oxytocin antagonists

Disclosed are spirocyclic compounds of the formula: The compounds of formula I are oxytocin antagonists useful in the treatment of preterm labor and dysmenorrhea, and for the stoppage of labor preporatory to Caesarian delivery. Also disclosed are pharmaceutical compositions containing these compounds as well as methods for preparing the compounds.